July 14, 2025 | Sarah Clark – Posted in Stratcann
Aurora Cannabis’ distribution centre, located in Brampton, Ontario, has received European Union Good Manufacturing Practice (EU-GMP) certification, according to a company press release.
The move, says the company, will increase its international export capabilities. The distribution centre joins Aurora’s group of manufacturing facilities in Canada and Europe, which are certified against EU standards.
Adding a fourth certified facility within its global network increases Aurora’s operational capacity to better serve international medical markets, says Jill Lau, Vice President of Canadian Operations at Aurora.
“Securing EU-GMP certification at manufacturing and distribution facilities within our network is an important validation of our differentiated approach to operating as a global medical cannabis company,” said Lau. “By adding certification for our distribution centre, we are now uniquely positioned to ensure patients worldwide have consistent access to superior quality medical cannabis from the largest Canadian exporter.”
EU-GMP certification is granted to companies whose production facilities meet the requirements under the EudraLex “Rules Governing Medicinal Products in the European Union,” and that can demonstrate a high degree of quality and consistency in their manufacturing procedures, a requirement for the export of medical cannabis products into Europe. EudraLex seeks to harmonize the interpretation and application of EU pharmaceutical legislation across member states
EU-GMP certification of Aurora’s distribution centre allows it to serve as a centralized site for more optimized and efficient receipt, storage, and distribution of materials and finished products internationally.
Earlier this year, Aurora announced the launch of its first German-cultivated medical cannabis, produced at the company’s EU-GMP facility in Leuna, Germany, one of only three licensed cannabis production facilities in the country.
The American cannabis company Tilray, which operates in Canada, the United States, Europe, Australia, and Latin America, was the first to receive a commercial cannabis production licence in the country in 2024. Aurora and the German company Demecan were also licensed for production in the country.
In July 2024, Aurora announced it was expanding its footprint in the emerging German cannabis market when the company was granted two licences by Germany’s Federal Institute for Drugs and Medical Devices (BfArM) under the country’s new Medical Cannabis Act (MedCanG).
Aurora’s medical cannabis production facility in Leuna, Saxony-Anhalt, in eastern Germany, has been operating since 2021. The facility cultivates approximately 1,000 kg of cannabis flower annually for the medical supply chain. In addition to Canada and Germany, Aurora operates in the UK, Poland, and Australia.
Aurora Cannabis reported $90.5 million in net revenue for the three months ended March 31, 2025 (Q4 2025), $27.6 million in gross profit, and a $17.2 million net loss.
Of Aurora’s medical cannabis net revenue, the majority ($41 million) in the most recent quarter came from sales into the international market, while $26.8 million in net revenue came from sales into Canada’s medical cannabis program.
View other cannabis industry news – Click Here